Published in Diabetes on September 01, 2003
PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 3.71
A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med (2011) 2.34
PPARalpha governs glycerol metabolism. J Clin Invest (2004) 1.79
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest (2014) 1.11
Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci U S A (2012) 1.09
Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br J Pharmacol (2005) 0.95
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol (2005) 0.95
Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab (2009) 0.94
Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta (2011) 0.92
PPARγ ablation sensitizes proopiomelanocortin neurons to leptin during high-fat feeding. J Clin Invest (2014) 0.92
The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res (2007) 0.90
Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res (2013) 0.86
Genetic and diet effects on Ppar-α and Ppar-γ signaling pathways in the Berlin Fat Mouse Inbred line with genetic predisposition for obesity. Lipids Health Dis (2010) 0.85
Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy. Exp Neurol (2016) 0.83
Linalool is a PPARα ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res (2014) 0.81
Protein and folic acid content in the maternal diet determine lipid metabolism and response to high-fat feeding in rat progeny in an age-dependent manner. Genes Nutr (2011) 0.81
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.80
Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats. Korean J Physiol Pharmacol (2012) 0.79
Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway. Br J Pharmacol (2015) 0.79
Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates. Biochem J (2005) 0.79
The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats. J Korean Med Sci (2007) 0.79
Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. World J Gastroenterol (2016) 0.79
Pioglitazone treatment increases food intake and decreases energy expenditure partially via hypothalamic adiponectin/adipoR1/AMPK pathway. Int J Obes (Lond) (2015) 0.77
Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD). PLoS One (2015) 0.77
55-week treatment of mice with the unani and ayurvedic medicine pomegranate flower ameliorates ageing-associated insulin resistance and skin abnormalities. Evid Based Complement Alternat Med (2011) 0.77
Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp (2010) 1.96
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proc Natl Acad Sci U S A (2005) 1.88
Central administration of ghrelin and agouti-related protein (83-132) increases food intake and decreases spontaneous locomotor activity in rats. Endocrinology (2004) 1.70
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest (2014) 1.61
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol (2010) 1.26
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol (2003) 1.23
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab (2003) 0.99
Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. PLoS One (2013) 0.99
Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology (2015) 0.98
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol (2005) 0.95
Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech (2012) 0.93
Gene expression profiling of individual hypothalamic nuclei from single animals using laser capture microdissection and microarrays. J Neurosci Methods (2008) 0.92
Upregulation of the brainstem preproglucagon system in the obese Zucker rat. Brain Res (2007) 0.92
Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One (2013) 0.91
Megaprimer method for polymerase chain reaction-mediated generation of specific mutations in DNA. Methods Mol Biol (2002) 0.91
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem (2002) 0.91
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab (2006) 0.90
Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat (2010) 0.89
Novel insight into the distribution of L-cells in the rat intestinal tract. Am J Transl Res (2013) 0.89
Hypothalamic cocaine-amphetamine regulated transcript (CART) is regulated by glucocorticoids. Brain Res (2003) 0.88
The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol (2012) 0.88
Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett (2008) 0.87
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab (2002) 0.87
Light-induced c-Fos expression in suprachiasmatic nuclei neurons targeting the paraventricular nucleus of the hamster hypothalamus: phase dependence and immunochemical identification. J Comp Neurol (2002) 0.86
Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clin Sci (Lond) (2006) 0.86
Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. Diabetes Care (2013) 0.86
Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Curr Pharm Des (2003) 0.85
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin (2012) 0.84
Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2. Brain Res Bull (2008) 0.84
The putative neuropeptide TAFA5 is expressed in the hypothalamic paraventricular nucleus and is regulated by dehydration. Brain Res (2008) 0.83
Characterization of beta-cell mass and insulin resistance in diet-induced obese and diet-resistant rats. Obesity (Silver Spring) (2009) 0.83
The effect of leptin receptor deficiency and fasting on cannabinoid receptor 1 mRNA expression in the rat hypothalamus, brainstem and nodose ganglion. Neurosci Lett (2009) 0.83
Projections from the raphe nuclei to the suprachiasmatic nucleus of the rat. J Chem Neuroanat (2003) 0.82
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res (2008) 0.80
Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice. J Pept Sci (2010) 0.79
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem (2007) 0.79
Selective estrogen receptor modulator effects in the rat brain. Neuroendocrinology (2002) 0.79
Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg Med Chem (2002) 0.79
Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity. J Pept Sci (2009) 0.79
Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake. J Pept Sci (2014) 0.78
[Why is weight loss so often followed by weight regain? Basal biological response as a possible explanation]. Ugeskr Laeger (2006) 0.78
Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity. Chembiochem (2010) 0.78
Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol (2008) 0.78
Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides. Eur J Pharmacol (2002) 0.78
Selective PPAR agonists for the treatment of type 2 diabetes. Ann N Y Acad Sci (2006) 0.78
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J Med Chem (2003) 0.77
Structure-activity relationships of dimeric PPAR agonists. Bioorg Med Chem Lett (2005) 0.76
Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helix variants of PYY3-36. J Pept Sci (2012) 0.75
Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor. Bioorg Med Chem Lett (2002) 0.75
Peptide architecture: adding an alpha-helix to the PYY lysine side chain provides nanomolar binding and body-weight-lowering effects. ChemMedChem (2010) 0.75
Design of potent PPARalpha agonists. Bioorg Med Chem Lett (2007) 0.75
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template. Bioorg Med Chem Lett (2003) 0.75